Does Beta-Thalassemia Affect HbA1c Results?
Yes, beta-thalassemia significantly affects HbA1c results, typically causing falsely low values due to shortened red blood cell lifespan, though the direction and magnitude of interference depends on the specific variant, transfusion status, and assay method used. 1
Mechanism of HbA1c Interference in Beta-Thalassemia
Beta-thalassemia interferes with HbA1c measurement through multiple pathways:
Any condition that shortens RBC survival or decreases mean RBC age produces falsely low HbA1c results regardless of the assay method used, which is the primary mechanism in beta-thalassemia. 1
Hemolytic anemia, characteristic of beta-thalassemia, results in falsely low HbA1c levels because red blood cells have less time for glucose exposure and glycation. 2
HbA1c cannot be measured and should not be reported in individuals with homozygous hemoglobin variants such as HbSS or HbEE; alternative markers like fructosamine or glycated albumin must be used instead. 1
Specific beta-thalassemia variants can produce either falsely elevated or falsely lowered HbA1c levels depending on the assay method used, as different HPLC methods have varying susceptibility to hemoglobin structural abnormalities. 2
Clinical Evidence from Beta-Thalassemia Patients
Recent case reports demonstrate the complexity of HbA1c interpretation in beta-thalassemia:
A case of rare β-thalassemia (HBB: c.170G>A, Hb J-Bangkok) showed an abnormally low HbA1c of 3.4% by HPLC despite impaired glucose tolerance and insulin resistance on OGTT, with an abnormal chromatogram peak indicating hemoglobin variant interference. 3
Conversely, α-thalassemia has been reported to cause discordantly high HbA1c results attributed to elevated hemoglobin H, demonstrating that thalassemia can affect HbA1c in either direction. 4
In transfusion-dependent thalassemia (TDT) patients, circulating hemoglobin is that of blood donors, and preliminary reports suggest HbA1c estimation in efficiently transfused patients may be valuable for diabetes monitoring. 5
A diabetic patient with thalassemia showed discrepancies between five-point glycemic profiles and HbA1c values, requiring simultaneous measurement of HbA1c and fructosamine for accurate assessment. 6
Recommended Diagnostic Approach
When beta-thalassemia is present or suspected, follow this algorithm:
Glucose testing will be necessary for screening, diagnosis, and management in individuals with disorders that affect red blood cell turnover, as HbA1c may provide spurious results regardless of the method used. 1
Use fructosamine or glycated albumin in clinical settings where abnormalities in red blood cell turnover, hemoglobin variants, or other interfering factors compromise HbA1c interpretation, though these reflect a shorter period of average glycemia (2-3 weeks vs. 2-3 months for HbA1c). 1
In children with beta-thalassemia major, fructosamine showed higher specificity for detecting prediabetes and higher sensitivity for identifying diabetes mellitus compared to HbA1c. 7
A hemoglobin variant or interference should be suspected if the HbA1c reading is surprisingly high or low, or significantly changed coincident with a change in laboratory method. 8, 9
Order hemoglobin electrophoresis or variant analysis to identify structural hemoglobin abnormalities when HbA1c is discordant with glucose monitoring. 9
Laboratory Considerations
Laboratories must account for beta-thalassemia interference:
Laboratories should be aware of potential interferences including hemoglobin variants that may affect HbA1c test results depending on the method used, and should consider the potential for interferences in their particular patient population when selecting assay methods. 1
Boronate affinity methods for HbA1c measurement are less susceptible to interference when hemoglobin variants are suspected. 9, 10
Checking the chromatogram may be helpful in interpreting HbA1c as well as identifying hemoglobinopathy, as abnormal peaks indicate variant interference. 3
Critical Clinical Pitfalls to Avoid
Never base treatment decisions solely on a single HbA1c measurement without consideration of glucose monitoring results in beta-thalassemia patients, as this may lead to unnecessary initiation or intensification of therapy or, conversely, missed diabetes diagnosis. 8, 9, 10
HbA1c should be interpreted with caution when there is a discrepancy with self-monitored blood glucose readings, especially in patients with suspected hemoglobinopathy. 8, 9
Do not average discordant HbA1c results, as this provides no clinically useful information and may lead to inappropriate treatment decisions. 9, 10
Avoid switching between different HbA1c methods for serial monitoring once a reliable method is established, as this introduces additional measurement variability. 9
In beta-thalassemia patients with diabetes, supplement HbA1c monitoring with self-monitoring of blood glucose and continuous glucose monitoring to capture glycemic patterns and variability. 9